Neil Jones To Step Down as Noven’s Vice President of Marketing & Sales

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that its Vice President of Marketing & Sales, W. Neil Jones, has indicated that he plans to leave the company in order to pursue other interests. Jones will remain with Noven for a transition period through the end of May 2008. Noven is working with a national executive recruiting firm to identify Jones’s successor.

"We thank Neil for his many contributions to Noven, and wish him well in his future endeavors," said Jeffrey F. Eisenberg, Executive Vice President of Noven and President of Novogyne Pharmaceuticals, Noven’s joint venture with Novartis Pharmaceuticals Corporation. "During his 11-year tenure at Noven, he helped establish a highly-effective and efficient marketing and sales organization, with core competencies that are serving us well as we build our specialty pharmaceutical business.” In connection with his decision to leave the organization, Noven recognized Jones with a career achievement award for his service.

"I am proud to have played a role in building an outstanding marketing and sales team," said Jones, “and I believe the team is well positioned to continue to help Noven advance its growth strategy." About Noven Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven’s business and operations are focused in three principal areas – transdermal drug delivery, the Novogyne joint venture, and its Noven Therapeutics specialty pharmaceutical unit.

About Noven
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven’s business and operations are focused in three principal areas – transdermal drug delivery, the Novogyne joint venture, and its Noven Therapeutics specialty pharmaceutical unit.

Safe Harbor Statement under the Private Litigation Reform Act of 1995
Except for historical information contained herein, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve substantial risks and uncertainties. Statements that are not historical facts, including statements that are preceded by, followed by, or that include, the words “believes,” “anticipates,” “plans,” “expects” or similar expressions and statements are forward-looking statements. Noven’s estimated or anticipated future results, product performance or other non-historical facts are forward-looking and reflect Noven’s current perspective on existing trends and information. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the current expectations of Noven and are subject to a number of risks and uncertainties that are subject to change based on factors that are, in many instances, beyond Noven's control.

These forward-looking statements include the risk that, for any number of reasons, Noven may not achieve its longer-term growth objectives and other goals. For additional information regarding these and other risks associated with Noven’s business, readers should refer to Noven’s Annual Report on Form 10-K as well as other reports filed from time to time with the Securities and Exchange Commission. Unless required by law, Noven undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:
Joseph C. Jones
Vice President – Corporate Affairs
305-253-1916